Can a heat probe through an endoscope treat pancreatic lesions?
NCT ID NCT07737171
First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This study tests whether a procedure called endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) can safely treat pancreatic lesions. The approach uses a special endoscope to deliver heat energy directly to the lesion. Researchers will enroll 60 people with pre-malignant or malignant pancreatic lesions to assess technical success and short-term complications.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Endoscopic ultrasound-guided radiofrequency ablation (RFA) — a procedure that uses a special endoscope to deliver heat energy to pancreatic lesions
- What this could lead to
- If successful, this approach could offer a less invasive treatment option for pancreatic lesions, potentially reducing the need for surgery.
- What could go wrong
- This is a small, early registry study (60 participants) focused on safety and technical success, not yet proving long-term benefit. Risks include pancreatitis, bleeding, and other complications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2026
- Expected to finish
-
Apr 2033
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Population is recruited from the PI's and Co-I's daily clinic
- Ages
-
18 years and older
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Diagnosis of any pancreatic pre-malignant lesion and/or pancreatic malignancy * Patients already undergoing EUS-RFA for treatment of pancreatic lesions clinically Exclusion Criteria: * Patients with co-existing malignancies of other organs (or a prior history of such) * Patients unable to provide informed consent * Patients unable to complete follow-up
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pancreatic cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
The University of Texas Health Science Center at Houston
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Three-Drug combo crack pancreatic Cancer's defenses?
- Can a blood test before pancreatic surgery predict a dangerous leak?
- New chemo cocktail targets pancreatic cancer at every stage
- Bacteria-Based immunotherapy targets pancreatic tumors in first human test
- Can a new radiation machine cut breath holds for cancer patients?
- Two oral drugs join chemotherapy in a bid to shrink pancreatic tumors